Skip to main content
. 2021 Sep 3;39:101075. doi: 10.1016/j.eclinm.2021.101075

Table 2.

Multivariable Logistic Regression Models for Hospitalization and Mortality Among Patients With Confirmed COVID-19

Models and independent variables Model Aa
Model Bb
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Hospitalization on date of index encounter (n=202,908)
 Hispanic 1.711 (1.642-1.784) <.001 1.690 (1.620-1.763) <.001
 Non-Hispanic Black 1.905 (1.836-1.977) <.001 1.810 (1.743-1.880) <.001
 Non-Hispanic Asian 1.440 (1.325-1.565) <.001 1.503 (1.381-1.636) <.001
 Non-Hispanic White Ref. Ref.
 Other/unknown 1.343 (1.287-1.400) <.001 1.379 (1.321-1.441) <.001
Hospitalization during follow-up (n=202,908)
 Hispanic 1.671 (1.611-1.733) <.001 1.700 (1.638-1.764) <.001
 Non-Hispanic Black 1.673 (1.618-1.729) <.001 1.578 (1.526-1.633) <.001
 Non-Hispanic Asian 1.272 (1.179-1.371) <.001 1.391 (1.288-1.501) <.001
 Non-Hispanic White Ref. Ref.
 Other/unknown 1.152 (1.109-1.197) <.001 1.283 (1.234-1.334) <.001
Death during follow-up among all patients (n=202,908)
 Hispanic 1.026 (0.940-1.121) 0.565 1.041 (0.952-1.138) 0.375
 Non-Hispanic Black 1.152 (1.077-1.233) <.001 1.110 (1.036-1.189) 0.003
 Non-Hispanic Asian 1.096 (0.935-1.285) 0.256 1.187 (1.011-1.395) 0.036
 Non-Hispanic White Ref. Ref.
 Other/unknown 1.020 (0.943-1.103) 0.623 1.040 (0.960-1.128) 0.337
Death during follow-up among patients hospitalized during follow-up (n=39,459)
 Hispanic 0.965 (0.869-1.073) 0.514 0.977 (0.879-1.087) 0.673
 Non-Hispanic Black 0.887 (0.816-0.965) 0.005 0.881 (0.809-0.959) 0.003
 Non-Hispanic Asian 1.177 (0.979-1.416) 0.083 1.205 (1.000-1.452) 0.050
 Non-Hispanic White Ref. Ref.
 Other/unknown 1.034 (0.934-1.144) 0.523 1.048 (0.945-1.162) 0.379

Ref., reference.

a

Adjusted for age group, sex, geographic region, insurance type, and index month. See Supplementary Tables 2-5 for full models.

b

Adjusted for age group, sex, geographic region, insurance type, index month, index body mass index, baseline Charlson comorbidity score category, baseline comorbidities, and baseline medication use. See Supplementary Tables 2-5 for full models.